RxDoctor Payments Data

Eileen Starbranch, MD

Psychiatry · Houston, TXNPI 1982671590

Payments from drug & device makers

$6,278in general payments, 2019–2025

Across 93 payments — averaging $67.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$2K
  • Alkermes, Inc.$1K
  • Teva Pharmaceuticals USA, Inc.$899
  • Johnson & Johnson$722
  • Indivior Inc.$472
  • E.r. Squibb & Sons, L.L.C.$381
  • plus $1K from 9 others

What the payments were for

  • Food & beverage$6,278100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,278 in reported general payments places this provider in the 85th percentile of 2,238 psychiatry providers in Texas.

See all psychiatry providers in Texas

Medicare billing

Part B allowed, 2024
$22,652
Medicare patients
51
Services billed
276

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate119$357,390
AustedoDeutetrabenazine20$158,435
Abilify MaintenaAripiprazole37$101,713
Paliperidone ErPaliperidone82$24,043
Effexor XrVenlafaxine Hcl24$21,096
VyvanseLisdexamfetamine Dimesylate49$18,872
Zyprexa ZydisOlanzapine13$17,189
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl70$12,330
Chlorpromazine Hcl43$9,486
Lurasidone Hcl63$8,165
Olanzapine OdtOlanzapine35$5,566
Aripiprazole62$4,157
Clomipramine Hcl14$3,718
Clozapine39$3,418
Ziprasidone Hcl46$2,780

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$722$357,390119 claims
Teva Pharmaceuticals USA, Inc.Austedo$899$158,43520 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$1,559$101,71337 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,238 psychiatry providers in Texas.

Other psychiatry in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →